- Home
- EDU vs CORT Comparison
EDU vs CORT Comparison
Compare EDU & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDU
- CORT
- Stock Information
- Founded
- EDU 1993
- CORT 1998
- Country
- EDU China
- CORT United States
- Employees
- EDU N/A
- CORT N/A
- Industry
- EDU Other Consumer Services
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- EDU Real Estate
- CORT Health Care
- Exchange
- EDU Nasdaq
- CORT Nasdaq
- Market Cap
- EDU 7.3B
- CORT 7.5B
- IPO Year
- EDU 2006
- CORT N/A
- Fundamental
- Price
- EDU $51.50
- CORT $71.34
- Analyst Decision
- EDU Buy
- CORT Strong Buy
- Analyst Count
- EDU 4
- CORT 4
- Target Price
- EDU $52.00
- CORT $142.00
- AVG Volume (30 Days)
- EDU 1.0M
- CORT 1.6M
- Earning Date
- EDU 07-30-2025
- CORT 07-28-2025
- Dividend Yield
- EDU 1.12%
- CORT N/A
- EPS Growth
- EDU 27.46
- CORT 8.36
- EPS
- EDU 2.29
- CORT 1.14
- Revenue
- EDU $4,793,786,000.00
- CORT $685,446,000.00
- Revenue This Year
- EDU $13.57
- CORT $35.83
- Revenue Next Year
- EDU $13.00
- CORT $35.24
- P/E Ratio
- EDU $23.39
- CORT $62.45
- Revenue Growth
- EDU 18.73
- CORT 30.93
- 52 Week Low
- EDU $40.66
- CORT $29.42
- 52 Week High
- EDU $87.26
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- EDU 55.12
- CORT 47.36
- Support Level
- EDU $53.14
- CORT $72.48
- Resistance Level
- EDU $54.35
- CORT $75.95
- Average True Range (ATR)
- EDU 1.41
- CORT 2.74
- MACD
- EDU 0.41
- CORT -0.16
- Stochastic Oscillator
- EDU 53.57
- CORT 31.69
About EDU New Oriental Education & Technology Group Inc.
New Oriental is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation, consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in the livestreaming e-commerce market.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.